Drugmaker Teva makes $40B bid for rival Mylan
Teva Pharmaceutical Gains Approval For Generic EpiPen, Mylan Shares Flat
Mylan Teva EpiPen Generic Auto-Injector Market
Mylan vs Teva Pharmaceuticals | Comparably
FDA Approves Teva's Generic EpiPen As Stock Rises
Teva or Mylan: Who Has the More Promising Revenue Trajectory?
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Generic EpiPen by Teva Wins FDA Nod After 2 Year Delay | Fierce Pharma
Teva, Mylan to jumpstart production of old malaria drug to fight coronavirus
Mylan, Generic Copaxone Punish Teva (NYSE:TEVA) | Seeking Alpha
$40B deal: Teva offers to buy Mylan
Teva makes $40 billion offer for Mylan
The Teva vs. Mylan drug war - The Jerusalem Post
Teva releases generic version of Mylan's EpiPen in limited doses in the U.S. - MarketWatch
Where a Teva-Mylan Deal Would Rank Among Big Pharma Companies
Teva's Deal for Mylan Shows Corporate Israel's M&A Hunger - WSJ
FDA swats down Teva's EpiPen copy, putting Mylan in cruise control | Fierce Pharma
Mylan sues generic rival Teva over 'sophisticated scheme' to block Copaxone copycats | Fierce Pharma
Mylan vs. Teva: Which Is the Better Generics Stock Ahead of Earnings?
Teva responds to Mylan backlash with planned launch of generic EpiPen | Healthcare IT News
Teva, Mylan Drop on Announcement of Epinephrine Injector Rival | Ctech
Teva makes $40.1 billion takeover bid for Mylan | Mint
Teva prices EpiPen generic at $300, same price as Mylan generic
Teva shares rival Mylan's pain as both hit two-year lows | Fierce Pharma
